Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
Holding DE:NOVA?
Track your performance easily
NOVA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€87.20 - €140.00
Previous Close€100.5
Volume611.00
Average Volume (3M)814.00
Market Cap
€446.49B
Enterprise Value€446.05B
Total Cash (Recent Filing)kr30.23B
Total Debt (Recent Filing)kr27.01B
Price to Earnings (P/E)35.3
Beta0.31
Next Earnings
Feb 05, 2025EPS Estimate
€0.84Last Dividend Ex-Date
Aug 16, 2024Dividend Yield0.98%
Share Statistics
EPS (TTM)2.85
Shares Outstanding4,462,229,293
10 Day Avg. Volume1,113
30 Day Avg. Volume814
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.15
Price to Sales (P/S)13.54
Price to Cash Flow (P/CF)82.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€148.06Price Target Upside47.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Novo Nordisk News
Bulls Say, Bears Say
Bulls Say
Market AccessNovo's CEO underscoring that 80% of Americans have access to Ozempic at ~$25/month or less and 90% of Americans have access at ~$50/month.
Product DevelopmentNext generation assets like CagriSema that improve upon the profiles of currently available incretins.
Scientific InnovationPh 1 data highlights potentially best-in-class oral efficacy from Novo's Amycretin, demonstrating placebo-adjusted mean change in body weight of 9.2% at the 50mg dose and 11.9% at the 2x 50mg dose at 12 weeks.
Bears Say
Pricing ChallengesNovo highlighting struggles the company has had with PBMs removing products from formulary when list prices were lowered.
Product StrategyThe strategy surrounding an oral weight loss agent is in flux.
Supply ConstraintsSupply constraints are expected to continue into 2025.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.57% Mutual Funds
4.94% Other Institutional Investors
93.41% Public Companies and
Individual Investors
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €87.20 and its highest was €140.00 in the past 12 months.
What is Novo Nordisk’s market cap?
Currently, no data Available
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Feb 05, 2025 which is in 72 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Nov 06, 2024. The company reported €0.831 earnings per share for the quarter, beating the consensus estimate of €0.83 by <€0.001.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of €0.35 which represents an annual dividend yield of 0.98%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is €0.84.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.831 in its last earnings report, beating expectations of €0.83. Following the earnings report the stock price went down -2.008%.
Which hedge fund is a major shareholder of Novo Nordisk?
Among the largest hedge funds holding Novo Nordisk’s share is Fisher Asset Management LLC. It holds Novo Nordisk’s shares valued at 2B.
---
Novo Nordisk Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€148.06 (47.32% Upside)
€148.06 (47.32% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 84%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.53%
12-Months-Change
Fundamentals
Return on Equity
88.20%
Trailing 12-Months
Asset Growth
39.65%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.
---
NOVA Earnings Call
Q3 2024
0:00 / 0:00
---
NOVA Stock 12 Month Forecast
Average Price Target
€148.06
▲(47.32% Upside)
Technical Analysis
Best Analysts Covering NOVA
1 Year
1 Year Success Rate
8/22 ratings generated profit
1 Year Average Return
+6.95%
reiterated a buy rating 13 days ago
Copying Sachin Jain's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +6.95% per trade.
---